Top Feature

Feb 12, 2018
Pharm Exec speaks to Jane Griffiths, Global Head of Actelion, about the current state of the industry's reputation and the work that needs to be done to further build trust with patients and the public.
Feb 12, 2018
Pharmaceutical Executive
The biotech sector has managed to elude the negative perceptions saddling traditional pharma these days. We examine the reasons why.
Feb 12, 2018
Pharmaceutical Executive
Lieutenant General (Ret) Rick Lynch, US Army, and Bob Jansen, CEO of Zensights, discuss the military-industry effort to instill the principles of adaptive leadership into today’s pharma leader.
Feb 12, 2018
Pharmaceutical Executive
Whether the pharma industry is navigating calm or choppy waters, it should be smarter and more assertive in telling its story to its stakeholders—most importantly, patients and the wider public.
Feb 11, 2018
Pharmaceutical Executive
In this Q&A, Richard Lajoie, the new head of Valeant Canada, shares his main priorities for the business, including growing its domestic manufacturing as a key cog globally.
Feb 02, 2018
Pharmaceutical Executive
2017 was a year of swings and momentum for the pharma and biotech markets. Is more stable footing ahead? Peter Young reports.
Jan 12, 2018
Pharmaceutical Executive
Bruno Strigini, CEO of Novartis Oncology, talks about the company’s pioneering path in cancer and the related broader issues such as pricing and value and new innovations in cancer science.
Dec 30, 2017
Pharmaceutical Executive
Pharm Exec details the latest approaches to combating disease and health crises on a global scale—including industry perspectives from those involved on the front lines.
Dec 11, 2017
Pharmaceutical Executive
Groundbreaking treatment approaches call for innovative commercialization strategies.
Dec 10, 2017
Pharmaceutical Executive
How Ruud Dobber is steering AstraZeneca’s US course as it navigates the complexities of a fast-evolving therapeutic market.
native1_300x100
lorem ipsum